<code id='0336F9F75C'></code><style id='0336F9F75C'></style>
    • <acronym id='0336F9F75C'></acronym>
      <center id='0336F9F75C'><center id='0336F9F75C'><tfoot id='0336F9F75C'></tfoot></center><abbr id='0336F9F75C'><dir id='0336F9F75C'><tfoot id='0336F9F75C'></tfoot><noframes id='0336F9F75C'>

    • <optgroup id='0336F9F75C'><strike id='0336F9F75C'><sup id='0336F9F75C'></sup></strike><code id='0336F9F75C'></code></optgroup>
        1. <b id='0336F9F75C'><label id='0336F9F75C'><select id='0336F9F75C'><dt id='0336F9F75C'><span id='0336F9F75C'></span></dt></select></label></b><u id='0336F9F75C'></u>
          <i id='0336F9F75C'><strike id='0336F9F75C'><tt id='0336F9F75C'><pre id='0336F9F75C'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment